Work

P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC)

Year: 2017

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2016.11.1500

Authors: Robert Doebele, Leora Horn, Alexander Spira, Zofia Piotrowska, Daniel Costa, Joel Neal, William Reichmann, David Kerstein, Shuanglian Li, Pasi Jänne

Institutions: University of Colorado Cancer Center, Vanderbilt-Ingram Cancer Center, Virginia Cancer Specialists, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Stanford Medicine, Stanford Cancer Institute, Stanford University, ARIAD Pharmaceuticals (United States), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2568412330

FWCI: 0.407

Cites:

Cited by: 4

Related to: 10